{"name":"Shanghai Biomabs Pharmaceutical Co., Ltd.","slug":"shanghai-biomabs-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CMAB008","genericName":"CMAB008","slug":"cmab008","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CMAB807 Injection","genericName":"CMAB807 Injection","slug":"cmab807-injection","indication":"Solid tumors (specific indication under investigation in Phase 3)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Remicade","genericName":"Remicade","slug":"remicade","indication":"Ankylosing spondylitis","status":"marketed"}]}],"pipeline":[{"name":"CMAB008","genericName":"CMAB008","slug":"cmab008","phase":"phase_3","mechanism":"CMAB008 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","indications":[],"catalyst":""},{"name":"CMAB807 Injection","genericName":"CMAB807 Injection","slug":"cmab807-injection","phase":"phase_3","mechanism":"CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses.","indications":["Solid tumors (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"Remicade","genericName":"Remicade","slug":"remicade","phase":"marketed","mechanism":"Tumor necrosis factor","indications":["Ankylosing spondylitis","Behcet's disease","Crohn's disease","Erythrodermic psoriasis","Plaque psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOV0hTc2FoTDQ1ZVRJTWtNVGU0ZHU4RGRCMFN5RFJ3MjB3VGtrdVJzenlfYU5aU0lyZ2NmRF9MbXlZTlppZGpFWURFaGZqZ2lKNkZUMERURUREajZDZFg1U0lydVg4cTJIa0lKZThHZFFCMk00WjllVVdJT2ZnNkZUaWphZHFzZzdneHc?oc=5","date":"2024-07-02","type":"regulatory","source":"BioWorld News","summary":"China approves first cetuximab biosimilar - BioWorld News","headline":"China approves first cetuximab biosimilar","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8gJBVV95cUxPRmEzaWZ4OEpmb2dTTEpYbXRYdFlmbkFFY0JtVW9oVDFteEo4dWRxN2NYMWFVNmwzdG5pSkFvek9xa21hRXRsaDhEV29fblpnLU5HWUtOYzVxVGFyOFBvUHhCUjB3REFjcTVmVjVEV2g0LXRnVGFXMFllUGMtQW1JbUJWNEtRdjk3em52eE1fY0Z6UDhlMG90WFNwWnFzNk5WME9XQktuaDVhX0didF8yM1JpTzRIMkpWSFl5c2xqSHB5WkVZWHdkb2lrT295YmI4LVV5YkJPOGNmTjEwYUFId2dWSXA5NXhvUlI4T19zTlM3VkNSR0VnM0NSMEViSE1BMU5STnliWnRYeS1GQW1lSmlua3NDVWFVaURWQV8xem1ZRjhGbGh2Wk1CaUJWclM4bXVpa1NQUkxoVVpuZXA3ZFZrLTgxUTRSVVY1TWFnUzUwSHFvd2UzbG8wVVNHVXhaamxMdDNELTktSmVtcWF6S1N3?oc=5","date":"2023-06-22","type":"pipeline","source":"prnewswire.com","summary":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis, Amgen, USB, Jiangsu HengRui Medicine, Shanghai JMT-Bio, Eli Lilly and Company, ","headline":"Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORnpZVkIwSTEtZ3BIUzAxaHE2RXJmTXl4NF9BVEVqQW5TM181RE5iSVRvOVpQdnYzYU9xRUxHYm4yN0lYSGlTMEwzWTZWSjRjVVhBWExHSDNBR01KZHF4dVRkclAwV3J1UUJ1dzJqTlRyN1FyZXR4ZWowN1NPSkN6MTZBNzd6bnNuYnlZYVdzSVBPSVE?oc=5","date":"2022-01-23","type":"patent","source":"Frontiers","summary":"Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects - Frontiers","headline":"Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}